pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,428 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1787Endpoints1391Fierce Biotech711BioSpace702BioPharma Dive526raps234onclive165fda recalls
therapy area
allOncology12335Rare Disease3228Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • Kardigan secures $400 million IPO to fund three clinical-stage cardiovascular candidates
    Kardigan, a New Jersey biotech focused on heart disease, announced it raised $400 million in a Nasdaq initial public offering. The capital will be directed toward advancing three clinical-stage dr…
    Endpoints · 4mo agoDealPositive↗ source
  • Biogen to acquire San Diego biotech RayThera in up to $1 billion deal
    Biogen announced it will acquire RayThera, a San Diego-based biotech, in a transaction valued at up to $1 billion. The agreement specifies that most of the payment will be made through milestone-b…
    Endpoints · 4mo agoDealPositive↗ source
← prev
page 76 of 98
next →
113
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1062
Pain778
Endocrinology & Metabolism777
Nephrology762
  • RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup
    RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea. The investment follows a growing pattern where la…
    Endpoints · 4mo agoDealNeutral↗ source
  • Innoviva revives Lyndra's long-acting oral drug platform
    Innoviva, a healthcare asset and royalties holding firm, announced it is bringing back Lyndra's long-acting oral drug delivery platform. The technology, which previously attracted more than $380 mi…
    Endpoints · 4mo agoPositive↗ source
  • Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1
    The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…
    Endpoints · 4mo agoNeutral↗ source
  • UK waitlist for Novo Nordisk’s Wegovy reaches 30,000 a week, tripling after approval
    Novo Nordisk’s weight‑loss injection Wegovy has been approved in the United Kingdom. Within a week of the green light, a major online pharmacy reported that its waiting list surged to roughly 30,00…
    Endpoints · 4mo agoApprovalPositive↗ source
  • Jazz Pharmaceuticals partners with AbCellera on T-cell engager program targeting GI cancers, deal up to $4.1 billion
    Jazz Pharmaceuticals announced a new collaboration with Canadian antibody company AbCellera to develop T-cell engager therapies aimed at gastrointestinal cancers. The agreement could be worth as m…
    Endpoints · 4mo agoDealPositive↗ source
  • Spot Bio raises $40M to begin mRNA therapy trials for Duchenne muscular dystrophy
    Spot Bio, a biotech startup operating in California and China, has started preclinical testing of a genetic medicine aimed at restoring the missing protein dystrophin in patients with Duchenne musc…
    Endpoints · 4mo agoDealPositive↗ source
  • FDA signals new window for companies with recent complete response letters after commissioner’s exit
    After FDA Commissioner Marty Makary left, the agency indicated it will reconsider drugs that received complete response letters in the past year. The move offers sponsors a chance to resubmit thei…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • FDA issues warning letters to 25 telehealth firms over misleading compounded GLP-1 marketing
    The U.S. Food and Drug Administration has sent warning letters to 25 telehealth companies. The letters cite concerns about how the firms promote compounded GLP-1 drugs used for weight loss. The ag…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Hackers claim to have stolen Novo Nordisk AI models and drug manufacturing recipes, demand $25M ransom
    Novo Nordisk disclosed that a hacker group says it has obtained the company's proprietary AI models and manufacturing recipes for its drugs. The group alleges the data is for sale and has demanded…
    Endpoints · 4mo agoNegative↗ source
  • FDA reverses earlier stance, grants uniQure accelerated approval pathway for Huntington's gene therapy
    On June 17, 2026, the U.S. Food and Drug Administration issued a second reversal, allowing biotech company uniQure to pursue an accelerated approval pathway for its gene therapy targeting Huntingto…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • FDA approves first generic single-dose baloxavir tablet for flu treatment and prevention
    FDA announced approval of the first generic version of Xofluza (baloxavir marboxil) tablets, a single-dose treatment for acute uncomplicated influenza and prophylaxis for patients five years of age…
    fda press · 4mo agoApprovalPositive↗ source
  • Triveni Bio secures $65M Series C as second eczema candidate enters clinical trials
    Triveni Bio announced a $65 million Series C financing round aimed at supporting its ongoing development programs. The round was co‑led by Ascenta Capital and Janus Henderson Investors, with parti…
    Endpoints · 4mo agoDealPositive↗ source
  • Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipeline
    Vedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round. The company raised $46 million from investors, whic…
    Endpoints · 4mo agoDealPositive↗ source
  • FDA approves OTC naloxone nasal spray Rextovy, expanding consumer access to overdose treatment
    The FDA announced approval of a new over-the-counter naloxone nasal spray called Rextovy, delivering 4 mg of naloxone hydrochloride for emergency reversal of opioid overdose. The product can be pu…
    fda press · 4mo agoApprovalPositive↗ source
  • FDA gives modest backing to Moderna’s flu vaccine, noting efficacy questions but no major concerns
    The FDA released briefing documents ahead of an advisory committee meeting on Moderna’s seasonal influenza vaccine. The agency’s assessment was described as tepid, highlighting some questions abou…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • FDA approves Colorado plan to import lower-cost drugs from Canada
    The U.S. Food and Drug Administration issued a letter confirming that Colorado may move forward with a pilot program to bring prescription medicines from Canada. The proposal aims to lower drug co…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • Edgewise Therapeutics moves heart disease drug into Phase 3 after updated Phase 2 data
    Edgewise Therapeutics announced on June 16, 2026 that it will advance its investigational therapy for a genetic heart disease into a registrational Phase 3 trial. The decision follows an updated a…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Eli Lilly acquires another pain biotech, its 11th deal this year, as FDA eyes decision on once‑weekly PrEP pill
    Eli Lilly announced the purchase of an Austin, Texas‑based pain biotechnology company, marking the 11th acquisition the Indianapolis‑based firm has completed in 2026. The deal expands Lilly's portf…
    Endpoints · 4mo agoDealNeutral↗ source
  • Health groups accuse HHS of rushing reinstatement of CDC vaccine advisory panel
    A coalition of health organizations has publicly charged the U.S. Department of Health and Human Services with attempting to accelerate the return of the CDC's Advisory Committee on Immunization Pr…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • UCSF spinout Kopra Bio secures $9.1M to advance virus therapy for glioblastoma in China
    Kopra Bio, a biotechnology company spun out of the University of California, San Francisco, announced it has raised $9.1 million in financing. The capital will be used to move its experimental viru…
    Endpoints · 4mo agoDealPositive↗ source
  • Be Bio halts hemophilia B cell-editing therapy trial
    Be Bio announced that it has terminated its clinical study of a hemophilia B therapy that used gene-editing of a patient’s own cells. The termination was recorded in a federal clinical-trials regi…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • OpenLoop Health says it can launch a virtual GLP-1 prescribing service in 24 hours
    OpenLoop Health says it can set up a telehealth operation that can prescribe GLP-1 medicines within a day. The company provides the medical‑group infrastructure that powers multiple virtual care p…
    Endpoints · 4mo agoNeutral↗ source
  • FDA grants accelerated approval for Tzield to delay insulin loss in children with newly diagnosed Stage 3 type 1 diabetes
    The U.S. Food and Drug Administration issued an accelerated approval on June 12, 2026 for Tzield (teplizumab) to slow the decline of insulin production in pediatric patients aged 8 to 17 who have r…
    fda press · 4mo agoApprovalPositive↗ source